Pembrolizumab in HNSCC With Residual Disease After Radiation

NCT02892201 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Low enrollment

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]